With its vaccine and its treatment against Covid-19, Pfizer has established itself as the most advanced pharmaceutical giant in the fight against the pandemic.
The group will invest more than 520 million euros in France over five years.
On the one hand, it is strengthening its production capacities, via an agreement with Novasep, which will produce the active ingredient of Paxlovid, its anti-Covid drug at its site in Mourenx (Pyrénées-Atlantiques).
On the other hand, Pfizer will invest in French biotechs and significantly increase its clinical trials with French patients.
Albert Bourla has been CEO of Pfizer since January 2019.
LE FIGARO.
- Why did you choose France to invest?
Albert Bourla.
-
It's a new France that has opened the doors to us, welcoming foreign investments, especially industrial ones.
The reforms carried out have made the country very competitive.
In addition, the know-how in health technologies is among the best in Europe, with…
This article is for subscribers only.
You have 91% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for 1€ the first month
I ENJOY IT
Already subscribed?
Login
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/H7U7FJNUZBG6BPL5PZCMGC6EUY.jpg)